Natalia Haraszkiewicz-Birkemeier, Ph.D.

Biography

Dr. Natalia Haraszkiewicz-Birkemeier is Strategy & Business Consultancy CEO at BioPharma First (BPF). She is a GCP, Strategy & Prince2 certified expert with over 15 years of expertise in biopharmaceutical product development with focus on strategy and operations. Prior to founding BPF she gained professional experience at biopharmaceutical, CRO and asset management organizations with headquarters in Europe, fulfilling senior leadership positions with increasing responsibility. She worked at Synthon BV / Byondis, a global company with a total profit of 300 M EU YoY, spending over 20% of GRE on R&D providing input into the portfolio strategic planning & partnerships. She built business relations and supported key customers at Future Diagnostics, a company operating in the IVD MD space with an outstanding customer base and was involved in Education activities at the Avans University of Applied Sciences (ATGM), where she was author of teaching/training programs organized with industry partners.

She provides consultancy on novel therapies in the context of Cell and Gene Therapies, biologicals, precision medicines and marketing approval strategies. She is a Mentor and Coach for start-ups and SMEs within EIT Health – the European Innovation & Technology Institute and co-founder of two start-ups. 

Dr. Haraszkiewicz-Birkemeier received her Master in (Bio)chemistry and Immunology from Wroclaw University in cooperation with the University of Bielefeld and her PhD from the University of Amsterdam, where a part of her dissertation was accomplished at the University of Bologna. After that she pursued her post-doc fellowship in Medicinal Chemistry in cooperation with Merck at the Free University in Amsterdam and accomplished two post-graduate degrees in Clinical Trials and an MBA with specialization in corporate finance and strategy, running her fellowship position at Gilde Healthcare, an investor managing over €2 B ($2 B) across two fund strategies: Venture & Growth and Private Equity.

In addition, she accomplished financial and business administration courses from top tire universities, the Wharton School of Business, and the International Rotterdam School of Management / Erasmus University.